Intranasal Dexmedetomidine Sedation for Ophthalmic Examinations in Children

NCT ID: NCT02077712

Last Updated: 2016-05-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-02-28

Study Completion Date

2017-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

2 ug/kg of intranasal dexmedetomidine could produce satisfactory sedation in more children for ophthalmic examinations than the sedative effect of 1ug/kg.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Dexmedetomidine is an a2-adrenergic receptor agonist that provides sedation without respiratory depression.Clinical trials have demonstrated that intranasal dexmedetomidine in a dose of 1ug/kg produces satisfactory sedation in between 53% and 57% of children at anaesthetic induction. There are also reports using higher doses of intranasal dexmedetomidine. The investigators compared the sedative effect of 1ug/kg intranasal dexmedetomidine with those of 2 ug/kg for ophthalmic examinations in children aged 2 months-10 years and hypothesised that the higher dose would produce satisfactory sedation in more children at the time of anaesthetic induction.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sniffs Drugs

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dexmedetomidine 1 ug/kg

1 ug/kg of intranasal dexmedetomidine

Group Type ACTIVE_COMPARATOR

intranasal dexmedetomidine

Intervention Type DRUG

1 or 2 ug/kg of intranasal dexmedetomidine

Dexmedetomidine 2 ug/kg

2 ug/kg of intranasal dexmedetomidine

Group Type ACTIVE_COMPARATOR

intranasal dexmedetomidine

Intervention Type DRUG

1 or 2 ug/kg of intranasal dexmedetomidine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

intranasal dexmedetomidine

1 or 2 ug/kg of intranasal dexmedetomidine

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ai Bei Ning

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Need sedation for ophthalmic examinations
* Children who had failed chloral hydrate sedation, i.e.there was no evidence of sedation 30 min following administration.
* With informed consent from parents

Exclusion Criteria

* Children with gastroesophageal reflux
* Children with nausea and vomiting
* Children with apnea in the past three months
* Children with recent pneumonia, exacerbation of asthma, bronchitis and upper respiratory tract infection
* Children with severe arrhythmias, heart failure and cardiac structural abnormalities
* Children with facial abnormalities, who is expected to be difficult with effective mask ventilation
* Children with severe neurological disease
* Children with moyamoya disease
* Children who is allergy to For dexmedetomidine or chloral hydrate
* Preterm children, weight \<2 kg
Minimum Eligible Age

2 Months

Maximum Eligible Age

6 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ministry of Health, China

OTHER_GOV

Sponsor Role collaborator

Sun Yat-sen University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Haotian Lin

Ophthalmologist

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Haotian Lin, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Zhongshan Ophthalmic Center, Sun Yat-sen University

Xiaoliang Gan, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Zhongshan Ophthalmic Center, Sun Yat-sen University

Weirong Chen

Role: STUDY_DIRECTOR

Zhongshan Ophthalmic Center, Sun Yat-sen University

Yizhi Liu, Ph.D.

Role: STUDY_CHAIR

Zhongshan Ophthalmic Center, Sun Yat-sen University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Zhongshan Ophthalmic Center

Guangzhou, Guangdong, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Haotian Lin

Role: CONTACT

862087330493

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Haotian Lin

Role: primary

862087330493

References

Explore related publications, articles, or registry entries linked to this study.

Ambi US, Joshi C, Ganeshnavar A, Adarsh E. Intranasal dexmedetomidine for paediatric sedation for diagnostic magnetic resonance imaging studies. Indian J Anaesth. 2012 Nov;56(6):587-8. doi: 10.4103/0019-5049.104588. No abstract available.

Reference Type BACKGROUND
PMID: 23325950 (View on PubMed)

Ray T, Tobias JD. Dexmedetomidine for sedation during electroencephalographic analysis in children with autism, pervasive developmental disorders, and seizure disorders. J Clin Anesth. 2008 Aug;20(5):364-368. doi: 10.1016/j.jclinane.2008.03.004.

Reference Type BACKGROUND
PMID: 18761245 (View on PubMed)

Li BL, Yuen VM, Song XR, Ye J, Ni J, Huang JX, Irwin MG. Intranasal dexmedetomidine following failed chloral hydrate sedation in children. Anaesthesia. 2014 Mar;69(3):240-4. doi: 10.1111/anae.12533. Epub 2014 Jan 21.

Reference Type RESULT
PMID: 24447296 (View on PubMed)

Fong CY, Lim WK, Li L, Lai NM. Chloral hydrate as a sedating agent for neurodiagnostic procedures in children. Cochrane Database Syst Rev. 2021 Aug 16;8(8):CD011786. doi: 10.1002/14651858.CD011786.pub3.

Reference Type DERIVED
PMID: 34397100 (View on PubMed)

Gan X, Lin H, Chen J, Lin Z, Lin Y, Chen W. Rescue Sedation With Intranasal Dexmedetomidine for Pediatric Ophthalmic Examination After Chloral Hydrate Failure: A Randomized, Controlled Trial. Clin Ther. 2016 Jun;38(6):1522-1529. doi: 10.1016/j.clinthera.2016.04.036. Epub 2016 May 24.

Reference Type DERIVED
PMID: 27229908 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.gzzoc.com

Homepage of Zhongshan Ophthalmic Center

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CCPMOH2010-China4

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.